Archive for August 2022
Good News Tuesday: Back-to-school assistance for Mass. students in need
Cradles to Crayons is partnering with local companies to prepare students for back-to-school in Massachusetts. Read More
Read MoreRecession worries have not put a dent in the hot job market
There’s yet another sign emerging that employers’ hiring challenges are likely to linger. Read More
Read MoreReport: CVS aims to buy health-tech platform Signify
CVS Health Corp. aims to make an acquisition in the health technology space, according to media reports. Read More
Read MoreEnvision Bank lays off dozens amid merger with Abington Bank
Envision Bank plans to lay off 50-plus workers as it completes its merger with Abington Bank. Read More
Read More‘Not enough:’ DataRobot cuts even more jobs after CEO switch
The internal turmoil that earlier this year invested Boston-based enterprise software provider DataRobot Inc. continues with more layoffs. Read More
Read MorePromising news from hypertension drug trial sends CinCor stock up more than 50%
The Waltham biotech is one of the few IPO success stories of 2022 so far. Read More
Read MoreEckersley says 2022 will be his final Red Sox broadcasting season
Dennis Eckersley, a former Red Sox pitcher whose sharp insights and sense of humor have provided a bright spot during a frustrating season for diehard Red Sox fans, will retire at season’s end. [Open to all readers] Read More
Read MoreBoston biotech gains $2B+ after late-stage trial in schizophrenia
The psychiatric drugmaker is riding high following positive results from a trial of a drug that works on the brain-immune-gut axis. Read More
Read MoreButtigieg on how Covid-19 affects America’s infrastructure priorities
Remote work hasn’t negated the need for massive infrastructure investments, according to Transportation Secretary Pete Buttigieg. But it did create some new priorities. Read More
Read MoreViewpoint: Congress has put a bull’s-eye on life sciences economy
Pioneer Institute fellow writes that Schumer-Manchin bill is bad for patients, a travesty for the New England life sciences economy, and hurts long-term drug affordability. Read More
Read More